Loading...
•
Dec 31, 2025
Relay Therapeutics Q4 2025 Earnings Report
Relay Therapeutics reported fourth quarter 2025 revenue under its Elevar license agreement and reduced operating expenses, while continuing to post a net loss.
Key Takeaways
In Q4 2025, Relay generated 7000000 in license revenue and narrowed its net loss to 54889000 as research and administrative expenses declined year-over-year, ending the quarter with over 554000000 in cash and investments.
Recorded 7000000 in license and other revenue in Q4 2025.
Reduced R&D expenses to 55415000 from 68075000 year-over-year.
Net loss improved to 54889000 compared to 76004000 in Q4 2024.
Ended the quarter with 554518000 in cash, cash equivalents and investments.
Revenue by Segment
Forward Guidance
The company expects its existing cash, cash equivalents and investments to fund operations and capital expenditures into 2029, with multiple clinical milestones anticipated in 2026.
Positive Outlook
- Approximately 554518000 in cash, cash equivalents and investments at Q4 end.
- Cash runway expected to fund operations into 2029.
- Initial Phase 1 data in vascular anomalies expected in 1H 2026.
- Breast cancer triplet data and frontline Phase 3 plans anticipated in 2026.
- Phase 1/2 breast cancer data presentation scheduled for March 16, 2026.
Challenges Ahead
- Continued net losses of 54889000 in Q4.
- Ongoing significant R&D spending of 55415000 in Q4.
- Clinical development risks associated with multiple trials.
- Dependence on successful regulatory interactions.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...